MarketAxess Holdings Inc. (MKTX) Jumps 6.08% on December 24

Equities Staff |

MarketAxess Holdings Inc. (MKTX) was among the biggest gainers on the Russell 2000 for Thursday December 24 as the stock popped 6.08% to $111.13, representing a gain of $6.37 per share. Some 195,924 shares traded hands on 2,454 trades, compared with an average daily volume of 306,111 shares out of a total float of 37.29 million. The stock opened at $105.28 and traded with an intraday range of $111.96 to $105.28.

After today's gains, MarketAxess Holdings Inc. reached a market cap of $4.14 billion. MarketAxess Holdings Inc. has had a trading range between $114.56 and $66.18 over the last year, and it had a 50-day SMA of $102.48 and a 200-day SMA of $94.36.

The stock has a P/E Ratio of 42.6.

MarketAxess Holdings Inc operates an electronic trading platform for corporate bonds and other types of fixed-income instruments.

MarketAxess Holdings Inc. is based out of New York, NY and has some 303 employees. Its CEO is Richard M. Mcvey.

For a complete fundamental analysis analysis of MarketAxess Holdings Inc., check out’s Stock Valuation Analysis report for MKTX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…